Identification of driver genes for severe forms of COVID-19 in a deeply phenotyped young patient cohort
Abstract The etiopathogenesis of severe COVID-19 remains unknown. Indeed given major confounding factors (age and co-morbidities), true drivers of this condition have remained elusive. Here, we employ an unprecedented multi-omics analysis, combined with artificial intelligence, in a young patient cohort where major co-morbidities have been excluded at the onset. Here, we established a three-tier cohort of individuals younger than 50 years without major comorbidities. These included 47 “critical” (in the ICU under mechanical ventilation) and 25 “non-critical” (in a noncritical care ward) COVID-19 patients as well as 22 healthy individuals. The analyses included whole-genome sequencing, whole-blood RNA sequencing, plasma and blood mononuclear cells proteomics, cytokine profiling and high-throughput immunophenotyping. An ensemble of machine learning, deep learning, quantum annealing and structural causal modeling led to key findings. Critical patients were characterized by exacerbated inflammation, perturbed lymphoid/myeloid compartments, coagulation and viral cell biology. Within a unique gene signature that differentiated critical from noncritical patients, several driver genes promoted severe COVID-19 among which the upregulated metalloprotease ADAM9 was key. This gene signature was replicated in an independent cohort of 81 critical and 73 recovered COVID-19 patients, as were ADAM9 transcripts, soluble form and proteolytic activity. Ex vivo ADAM9 inhibition affected SARS-CoV-2 uptake and replication in human lung epithelial cells. In conclusion, within a young, otherwise healthy, COVID-19 cohort, we provide the landscape of biological perturbations in vivo where a unique gene signature differentiated critical from non-critical patients. The key driver, ADAM9, interfered with SARS-CoV-2 biology. A repositioning strategy for anti-ADAM9 therapeutic is feasible.One sentence summary Etiopathogenesis of severe COVID19 in a young patient population devoid of comorbidities..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 27. Juni Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.06.21.21257822 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI03207302X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI03207302X | ||
| 003 | DE-627 | ||
| 005 | 20230429090118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210628s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.06.21.21257822 |2 doi | |
| 035 | |a (DE-627)XBI03207302X | ||
| 035 | |a (biorXiv)10.1101/2021.06.21.21257822 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Carapito, Raphael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of driver genes for severe forms of COVID-19 in a deeply phenotyped young patient cohort |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The etiopathogenesis of severe COVID-19 remains unknown. Indeed given major confounding factors (age and co-morbidities), true drivers of this condition have remained elusive. Here, we employ an unprecedented multi-omics analysis, combined with artificial intelligence, in a young patient cohort where major co-morbidities have been excluded at the onset. Here, we established a three-tier cohort of individuals younger than 50 years without major comorbidities. These included 47 “critical” (in the ICU under mechanical ventilation) and 25 “non-critical” (in a noncritical care ward) COVID-19 patients as well as 22 healthy individuals. The analyses included whole-genome sequencing, whole-blood RNA sequencing, plasma and blood mononuclear cells proteomics, cytokine profiling and high-throughput immunophenotyping. An ensemble of machine learning, deep learning, quantum annealing and structural causal modeling led to key findings. Critical patients were characterized by exacerbated inflammation, perturbed lymphoid/myeloid compartments, coagulation and viral cell biology. Within a unique gene signature that differentiated critical from noncritical patients, several driver genes promoted severe COVID-19 among which the upregulated metalloprotease ADAM9 was key. This gene signature was replicated in an independent cohort of 81 critical and 73 recovered COVID-19 patients, as were ADAM9 transcripts, soluble form and proteolytic activity. Ex vivo ADAM9 inhibition affected SARS-CoV-2 uptake and replication in human lung epithelial cells. In conclusion, within a young, otherwise healthy, COVID-19 cohort, we provide the landscape of biological perturbations in vivo where a unique gene signature differentiated critical from non-critical patients. The key driver, ADAM9, interfered with SARS-CoV-2 biology. A repositioning strategy for anti-ADAM9 therapeutic is feasible.One sentence summary Etiopathogenesis of severe COVID19 in a young patient population devoid of comorbidities. | ||
| 700 | 1 | |a Li, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Helms, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Carapito, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Gujja, Sharvari |e verfasserin |4 aut | |
| 700 | 1 | |a Rolli, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Guimaraes, Raony |e verfasserin |4 aut | |
| 700 | 1 | |a Malagon-Lopez, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Spinnhirny, Perrine |e verfasserin |4 aut | |
| 700 | 1 | |a Mohseninia, Razieh |e verfasserin |4 aut | |
| 700 | 1 | |a Hirschler, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Bastard, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Gervais, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Danion, François |e verfasserin |4 aut | |
| 700 | 1 | |a Ruch, Yvon |e verfasserin |4 aut | |
| 700 | 1 | |a Schenck-Dhif, Maleka |e verfasserin |4 aut | |
| 700 | 1 | |a Collange, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Chamaraux-Tran, Thiên-Nga |e verfasserin |4 aut | |
| 700 | 1 | |a Molitor, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Pichot, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Tahar, Ouria |e verfasserin |4 aut | |
| 700 | 1 | |a Bibi-Triki, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Haiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Nicodème |e verfasserin |4 aut | |
| 700 | 1 | |a Mayeur, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Larnicol, Annabel |e verfasserin |4 aut | |
| 700 | 1 | |a Laumond, Géraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Frappier, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Hanauer, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Macquin, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Stemmelen, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Simons, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Fafi-Kremer, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Goichot, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Drenou, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Kuteifan, Khaldoun |e verfasserin |4 aut | |
| 700 | 1 | |a Pottecher, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Mertes, Paul-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Kailasan, Shweta |e verfasserin |4 aut | |
| 700 | 1 | |a Aman, M. Javad |e verfasserin |4 aut | |
| 700 | 1 | |a Pin, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Viari, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Sanlaville, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Sibilia, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Tharaux, Pierre-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Casanova, Jean-Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Hansmann, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Lidar, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Radosavljevic, Mirjana |e verfasserin |4 aut | |
| 700 | 1 | |a Gulcher, Jeffrey R. |e verfasserin |4 aut | |
| 700 | 1 | |a Meziani, Ferhat |e verfasserin |4 aut | |
| 700 | 1 | |a Moog, Christiane |e verfasserin |4 aut | |
| 700 | 1 | |a Chittenden, Thomas W. |e verfasserin |4 aut | |
| 700 | 1 | |a Bahram, Seiamak |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 27. Juni |
| 773 | 1 | 8 | |g year:2021 |g day:27 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.06.21.21257822 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 27 |c 06 | ||
| 953 | |2 045F |a 570 | ||